Health · 3 views
Next-Gen Anticoagulant Lands FDA Nod for Secondary Stroke Prevention
Health 
Story intelligence
Coverage Single outlet Single-outlet story
Views 3 Community interest
Brief read Under 1 min brief 24 words
Summary
(MedPage Today) -- The FDA approved asundexian (Sunharbo) as the first factor XIa (FXIa) inhibitor for secondary stroke prevention, the agency announced on Monday.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Predicting long-term pain after freezing nerves in surgeryContinue reading
- ADA Publications Chief ResignsContinue reading
- EEG analysis estimates depressive symptom severity in adults not receiving psychiatric treatmentContinue reading
- Resistance training key to maintaining muscle function during GLP-1 weight loss, study showsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow